Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Am Med Dir Assoc ; 20(7): 893-898, 2019 07.
Article in English | MEDLINE | ID: mdl-30826270

ABSTRACT

OBJECTIVES: Older age is associated with higher risk of death during acute exacerbations of chronic obstructive pulmonary disease (AE-COPD). Older patients hospitalized for AE-COPD often require post-acute care after acute phase. The aim of this study was to evaluate components of a comprehensive geriatric assessment and clinical/laboratory parameters, in order to find predictors of in-hospital mortality and need for post-acute care in patients aged 80 and older hospitalized for AE-COPD. DESIGN: Prospective observational study. SETTING: Hospital assessment. PARTICIPANTS: 121 patients consecutively admitted to an internal medicine and geriatrics department for AE-COPD. MEASURES: Activities of Daily Living (ADL) Hierarchy scale, Geriatric Index of Comorbidity, cognitive impairment, and clinical and laboratory parameters were collected. RESULTS: Mean age: 87.0 ± 4.9 years; male: 54.5%. In-hospital mortality (18.2% of patients) was significantly associated with functional disability, high comorbidity, cognitive impairment, anemia, older age, lower albumin, higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) and white blood cell levels, oral corticosteroids taken before admission, and no angiotensin-converting enzyme inhibitors or angiotensin receptor blockers taken before admission. In a stepwise logistic regression, functional dependence (P = .006), cognitive impairment (P = .038), and oral corticosteroids therapy before hospitalization (P = .035) were independently associated with a higher risk of in-hospital mortality. Among laboratory parameters, only NT-proBNP remained significantly associated with in-hospital mortality (P = .026). The need for post-acute care (18.2% of survivors) was associated with older age, higher admission Pco2, greater comorbidity, and cognitive impairment. In a stepwise logistic regression, only cognitive impairment (P = .016) and ln_Pco2 (P = .056) confirmed their association with the need for post-acute care. CONCLUSIONS/IMPLICATIONS: Preadmission functional dependence, cognitive impairment, and corticosteroid use, plus elevated NT-proBNP at admission are risk factors for mortality during an AE-COPD in the oldest old. Therefore, medical providers should consider these, as well as the patient's advance directives, in planning hospital care. Furthermore, providers should arrange especially careful posthospitalization monitoring and frequent follow-up of individuals with cognitive impairment and baseline hypercapnia.


Subject(s)
Hospital Mortality/trends , Pulmonary Disease, Chronic Obstructive/physiopathology , Subacute Care , Acute Disease , Aged, 80 and over , Cognitive Dysfunction , Female , Forecasting , Geriatric Assessment/methods , Humans , Male , Prospective Studies , Pulmonary Disease, Chronic Obstructive/psychology , Pulmonary Disease, Chronic Obstructive/therapy
2.
J Clin Hypertens (Greenwich) ; 20(9): 1230-1237, 2018 09.
Article in English | MEDLINE | ID: mdl-29981188

ABSTRACT

Blood pressure (BP) changes and risk factors associated with pulse pressure (PP) increase in elderly people have rarely been studied using ambulatory blood pressure monitoring (ABPM). The aim is to evaluate 10-year ambulatory blood pressure (ABP) changes in older hypertensives, focusing on PP and its associations with mortality. An observational study was conducted on 119 consecutive older treated hypertensives evaluated at baseline (T0) and after 10 years (T1). Treatment adherence was carefully assessed. The authors considered clinical parameters at T1 only in survivors (n = 87). Patients with controlled ABP both at T0 and T1 were considered as having sustained BP control. Change in 24-hour PP between T0 and T1 (Δ24-hour PP) was considered for the analyses. Mean age at T0: 69.4 ± 3.7 years. Females: 57.5%. Significant decrease in 24-hour, daytime, and nighttime diastolic BP (all P < .05) coupled with an increase in 24-hour, daytime, and nighttime PP (all P < .05) were observed at T1. Sustained daytime BP control was associated with lower 24-hour PP increase than nonsustained daytime BP control (+2.23 ± 9.36 vs +7.79 ± 8.64 mm Hg; P = .037). The association between sustained daytime BP control and Δ24-hour PP remained significant even after adjusting for age, sex, and 24-hour PP at T0 (ß=0.39; P = .035). Both 24-hour systolic BP and 24-hour PP at T0 predicted mortality (adjusted HR 1.07, P = .001; adjusted HR 1.25, P < .001, respectively). After ROC comparison (P = .001), 24-hour PP better predicted mortality than 24-hour systolic BP. The data confirm how ABP control affects vascular aging leading to PP increase. Both ambulatory PP and systolic BP rather than diastolic BP predict mortality in older treated hypertensives.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure/physiology , Hypertension/drug therapy , Hypertension/mortality , Aged , Aged, 80 and over , Antihypertensive Agents/pharmacology , Blood Pressure Monitoring, Ambulatory , Circadian Clocks , Female , Humans , Hypertension/physiopathology , Male , Prognosis , Survival Analysis , Treatment Adherence and Compliance
3.
J Hypertens ; 36(2): 445, 2018 02.
Article in English | MEDLINE | ID: mdl-29611837

Subject(s)
Aldosterone , Renin , Humans
4.
Respiration ; 95 Suppl 1: 22-29, 2018.
Article in English | MEDLINE | ID: mdl-29705783

ABSTRACT

Cardiovascular (CV) comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with increased morbidity and mortality, especially in old and very old subjects. The question if long-acting beta-agonist and long-acting muscarinic antagonist could be associated with the increased prevalence of CV-related adverse effects has puzzled, particularly in the past, specialists involved in the management of respiratory diseases. The safety of these compounds has scarcely been tested in patients aged ≥ 65 years with CV comorbidities, since randomized controlled trials rarely include this subpopulation. However, the fixed combination indacaterol/glycopyrronium has shown a favorable CV safety profile in both healthy volunteers and COPD patients. Thus, we aimed to assess the CV safety pro-- file of the fixed combination indacaterol/glycopyrronium 110/50 µg in a series of COPD patients aged ≥ 80 years with several comorbidities. Our results indicate that this combination is safe in the comorbid elderly, since no significant electrocardiographic abnormalities were recorded after the administration of the inhaled therapy. Only rare and nonclinically significant changes in heart rate and corrected QT interval duration were evident, mainly in females and in patients with concomitant impaired kidney function.


Subject(s)
Adrenergic beta-2 Receptor Agonists/adverse effects , Cardiovascular Diseases/chemically induced , Glycopyrrolate/adverse effects , Indans/adverse effects , Muscarinic Antagonists/adverse effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Quinolones/adverse effects , Administration, Inhalation , Aged, 80 and over , Drug Therapy, Combination , Electrocardiography , Female , Humans , Male
5.
J Am Med Dir Assoc ; 19(4): 342-347, 2018 04.
Article in English | MEDLINE | ID: mdl-29128438

ABSTRACT

OBJECTIVES: Cardiovascular diseases are mainly related to hypertension and dyslipidemia and increase with aging because of the larger time span for these risk factors to damage arterial blood vessels. The impact of cardiovascular drug therapy on outcomes in the very elderly hospitalized is still not well established. The aim of our study was to evaluate the associations between cardiovascular therapy and in-hospital mortality in very elderly hypertensives. DESIGN: Prospective observational study. SETTING: Hospital assessment. PARTICIPANTS: 310 very elderly hypertensive patients admitted to our Internal Medicine and Geriatrics Department for medical conditions. MEASUREMENTS: Main comorbidities, laboratory parameters, and cardiovascular drug therapy taken before admission were considered for the analyses. RESULTS: The mean age was 88.1 ±â€¯5.1 years, with female prevalence of 57.4%. Among cardiovascular drugs taken before admission, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers and statins were those associated with lower in-hospital mortality, even after adjusting for covariates (age, hemoglobin, albumin, acute kidney injury, ADL Hierarchy Scale, NT-proBNP levels) [odds ratio (OR) = 0.46, P = .045, and OR = 0.21, P = .008, respectively]. No difference regarding in-hospital mortality was found between ACE inhibitors and angiotensin receptor blockers (P = .414). CONCLUSION: ACE inhibitors/angiotensin receptor blockers and statins, through their beneficial effects on the cardiovascular system, have a positive impact on survival in very elderly hospitalized patients. Our data confirm the important role of such drugs even in this particular population with a mean age higher than 88 years, where scientific evidence is still scanty.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Cardiovascular Diseases/drug therapy , Hospital Mortality/trends , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hypertension/drug therapy , Hypertension/mortality , Aged, 80 and over , Angiotensin Receptor Antagonists/administration & dosage , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Drug Therapy, Combination , Female , Frail Elderly , Hospitalization/statistics & numerical data , Humans , Hypertension/diagnosis , Italy , Male , Prognosis , Prospective Studies , Risk Assessment , Severity of Illness Index , Survival Rate , Treatment Outcome
6.
J Hypertens ; 35(11): 2315-2322, 2017 11.
Article in English | MEDLINE | ID: mdl-28614094

ABSTRACT

OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACE-I) and AT1 blockers (ARB) are commonly used antihypertensive drugs, but several factors may affect their effectiveness. We evaluated the associations between ambulatory blood pressure (BP) monitoring (ABPM) parameters and plasma renin activity (PRA)-to-plasma aldosterone concentration (PAC) ratio (RAR) to test renin-angiotensin-aldosterone system inhibition in essential hypertensive patients treated with ACE-I or ARB for at least 12 months. METHODS: We evaluated 194 consecutive patients referred to our Hypertension Centre. ABPM, PRA and PAC tests were performed without any changes in drug therapy. RAR, PRA and PAC tertiles were considered for the analyses. RESULTS: Mean age: 57.4 ±â€Š12.0 years; male prevalence: 63.9%. No differences between RAR tertiles regarding the use of ACE-I or ARB (P = 0.385), as well as the other antihypertensive drug classes, were found. A reduction of all ABPM values considered (24-h BP, daytime BP and night-time BP and 24-h pulse pressure (PP), daytime PP and night-time PP) and a better BP control were observed at increasing RAR tertiles, with an odds ratio = 0.12 to be not controlled during night-time period for patients in the third tertile compared with patients in the first tertile (P < 0.001). This association remained significant even after adjusting for 24-h BP control. All the associations were also confirmed for PRA tertiles, but not for PAC tertiles. CONCLUSION: Higher RAR values indicate effective renin-angiotensin-aldosterone system inhibition and lower night-time and pulse pressures in real-life clinical practice. It could be a useful biomarker in the management of essential hypertensive patients treated with ACE-I or ARB.


Subject(s)
Aldosterone/blood , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biomarkers/blood , Essential Hypertension/drug therapy , Renin/blood , Blood Pressure , Blood Pressure Monitoring, Ambulatory , Circadian Rhythm , Essential Hypertension/blood , Essential Hypertension/physiopathology , Female , Humans , Male , Middle Aged , Renin-Angiotensin System/drug effects
7.
High Blood Press Cardiovasc Prev ; 24(2): 115-126, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28378069

ABSTRACT

Prevalence of cardiovascular (CV) disease is increasing worldwide. One of the most important risk factors for CV disease is hypertension that is very often related to obesity and metabolic syndrome. The search for key mechanisms, linking high blood pressure (BP), glucose and lipid dysmetabolism together with higher CV risk and mortality, is attracting increasing attention. Cardiac natriuretic peptides (NPs), including ANP and BNP, may play a crucial role in maintaining CV homeostasis and cardiac health, given their impact not only on BP regulation, but also on glucose and lipid metabolism. The summa of all metabolic activities of cardiac NPs, together with their CV and sodium balance effects, may be very important in decreasing the overall CV risk. Therefore, in the next future, cardiac NPs system, with its two receptors and a neutralizing enzyme, might represent one of the main targets to treat these multiple related conditions and to reduce hypertension and metabolic-related CV risk.


Subject(s)
Atrial Natriuretic Factor/blood , Blood Pressure , Cardiovascular Diseases/blood , Hypertension/blood , Natriuretic Peptide, Brain/blood , Animals , Atrial Natriuretic Factor/therapeutic use , Biomarkers/blood , Blood Pressure/drug effects , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Hypertension/physiopathology , Natriuretic Peptide, Brain/therapeutic use , Prognosis , Receptors, Atrial Natriuretic Factor/metabolism , Risk Assessment , Risk Factors , Signal Transduction
8.
J Clin Hypertens (Greenwich) ; 19(5): 472-478, 2017 May.
Article in English | MEDLINE | ID: mdl-28026096

ABSTRACT

Patients with type 2 diabetes mellitus are at high risk for atherosclerotic disease, and proper blood pressure measurement is mandatory. The authors examined the prevalence of an interarm difference (IAD) in blood pressure and its association with cardiovascular risk factors and organ damage (nephropathy, retinopathy, left ventricular hypertrophy, and vascular damage) in a large diabetic population. A total of 800 consecutive patients with type 2 diabetes mellitus were evaluated with an automated simultaneous bilateral device (men: 422 [52.8%]; mean age: 68.1±12.2 years). Diabetic patients with systolic IAD ≥5 and systolic IAD ≥10 mm Hg showed an increased risk of having vascular damage (adjusted odds ratios: 1.73 and 2.49, respectively) and higher pulse pressure. IAD is highly prevalent in patients with diabetes, is associated with vascular damage, even for IAD ≥5 mm Hg, and should be accurately obtained to avoid underdiagnosis and undertreatment of hypertension.


Subject(s)
Arm/blood supply , Blood Pressure/physiology , Diabetes Mellitus, Type 2/physiopathology , Aged , Aged, 80 and over , Atherosclerosis/complications , Atherosclerosis/physiopathology , Blood Pressure Determination/methods , Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Diabetic Nephropathies/physiopathology , Diabetic Retinopathy/complications , Diabetic Retinopathy/physiopathology , Female , Humans , Hypertension/physiopathology , Hypertrophy, Left Ventricular/complications , Hypertrophy, Left Ventricular/physiopathology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Risk Factors , Systole/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...